Anaconda BioMed

Anaconda is honored to be among the 72 start-ups from 24 European countries that have been selected to join the Scaling Club of the European Innovation Council (EIC), an exclusive community of the region's 120+ most promising high-tech start-ups. #EICScalingClub #Cohort2 #Innovation #Europe #Startup #investment #EUInnovates #EUInnovation

"This is vindication that their device is considered reasonably safe and effective for actual trial on patients in the United States."   MTI speaks to Dr. Adnan Siddiqui, MD, PhD about Anaconda BioMed’s ANA Funnel Catheter, its enrolment in the ATHENA study and IDE approval. https://lnkd.in/eiNmY3Q6 #MedTech #Catheters #IDE

Anaconda Biomed are developing next-generation thrombectomy systems. They have announced a conditional IDE approval from the U.S. FDA to begin the ATHENA study of its ANA Funnel Catheter. This prospective, randomized, multi-center study will assess the safety and effectiveness of the ANA Funnel Catheter in combination with a stent retriever for mechanical #thrombectomy. “The IDE approval marks an exciting milestone in our company’s mission to deliver new, safe, and effective solutions that can meaningfully improve the treatment of stroke,” said Anaconda Biomed CEO Francois Salmon. Dr.Adnan Siddiqui, MD, PhD, coordinating investigator of the ATHENA study, added, “The neurointerventional community is eager to assess this innovative technology, which is designed to enhance the efficiency of mechanical thrombectomy. Even a small difference in revascularization success after one pass can have a profound impact on the clinical outcomes of people with ischemic stroke.” Studies indicate that flow arrest during mechanical thrombectomy can improve revascularization rates and clinical outcomes. However, this approach has been underutilized due to current device limitations. Anaconda Biomed’s ANA Funnel Catheter is uniquely designed to facilitate flow arrest during clot retrieval. Upon IRB approval, the ATHENA study will be conducted at up to 40 U.S. and international centers, enrolling patients with acute #ischemic stroke treated within 24 hours of symptom onset. The study will report acute reperfusion success after a single thrombectomy pass and procedural safety between study arms. Congratulations to Francois, Ofir Arad, David Harari, Hendrik Lambert and the wider Anaconda BioMed team! #neurointerventional #idestudy #neurovascular #stroke

We have very exciting news: ''We have received conditional IDE approval from the U.S. Food and Drug Administration to begin the ATHENA study of its ANA Funnel Catheter'' Press Release: https://lnkd.in/duYyKEjc Thank you very much 🐍

Remembering with a lot of emotional hangover the last team building we did last June, "CONDAYAK" 🌊. A very special moment was the celebration of our colleagues who have completed 5 years in Anaconda! 😍 As always we enjoyed two wonderful days together as a team 😜. We are lucky to be part of an organisation where people are at the centre of everything, and we work to create connections outside the workplace 💚. #CONDAYAK #teambulding #newexperiences

Today in Catalonia we celebrate one of the most beautiful days of the year, Sant Jordi🌹, and our office has been filled with flowers and sweets. Happy Sant Jordi day to all of you 🌹 🐲 📖  

Our CEO, Francois Salmon, was at the MedTech Strategist in Dublin to demonstrate Anaconda Biomed's dedication to finding a safe and efficient way to perform a mechanical thrombectomy. A big thank you to everyone involved and to all those who support our project 🐍 Innogest Capital Ysios Capital Omega Funds Asabys Partners #MedTechStrategist #MedTechInnovation

Yesterday was a very special day, it was Anaconda's 9th anniversary!!! 🐍 🎂 Thank you to all the people who make this project possible, you are a fundamental part of our work.🧡 Innogest Capital, Ysios Capital, Omega Funds, Asabys Partners Lunch: L'obrador catering Delicious!

Happy international Women's Day 💜 🐍